Dr. Reddy has recorded a 115% growth in net profit for 1QFY02, much in line with market expectations. The figures for the current quarter is on a consolidated basis with Cheminor drugs and American Remedies. To provide meaningful comparison, previous quarter numbers are also on a consolidated basis. International formulations sales and a breakthrough in generic business contributed to the surge in net profit. Sales growth was driven primarily by 89% growth in branded formulations exports. Domestic branded formulations grew by 21%, outsmarting the industry growth rates.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Fully Diluted Earnings per share*
P/E (at current price)
Operating margins registered a healthy increase of 390 basis points on the back of higher-margin formulation exports and a significant breakthrough in the US generics market. The margins in the US generics market are more than 50%. Savings in interest cost also contributed significantly to net profit growth. Dr. Reddy's utilised US$ 69 m from net ADR proceeds of US$ 124 m to repay its debt, which is in line with the ADR utilisation projections.
In a related development, the company cleared the final hurdle for launching 40 mg fluoxetine (generic of Eli Lilly's block buster product Prozac) in the US markets with a six month marketing exclusivity. Dr.Reddy's would be the first Indian company to receive such exclusivity which ensures very high margins for its products. The company expects to launch the product in first week of August.
At the current market of Rs 1,690, the stock trades at a P/e of 30x the annualised earnings for 1QFY02. . The company has also been quick in deploying its ADR funds, which removes concerns for a considerable drop in RoCE. The highlights of the first quarter results is the significant breakthrough in the US generics market. The windfall gains from fluoxetine exclusivity is expected to be the key earnings driver in the coming quarters (approximately the company is expected to earn US$ 16 m from marketing). Other valuation triggers for the stock at this point of time are probable acquisitions (the company has reserved US$ 78 m towards this), windfall gains from research pipeline and other breakthrough's in the
generic market.. However, any negative news from R&D front or delay in lauching products for the generics market could lead to a fall in valuations as the markets have built lot of expectations from the company.
Dr. Reddy's has decided to go for stock split in the ratio of 2:1.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407